A Phase II Single Arm Study of Degarelix in Men With Castrate Resistant Prostate Cancer With a Rising Prostate-Specific Antigen (PSA) Despite LHRH Agonist Therapy.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Jul 2012 New trial record
- 28 Jun 2012 Biomarkers information updated